MarkWide Research

Sale!

Prenatal and Newborn Genetic Testing Market Analysis 2022-2030

No of Pages: 174
Delivery Format: PDF+ Excel

$2,950.00

Prenatal and Newborn Genetic Testing Market Overview

Prenatal and Newborn Genetic Testing Market size was estimated at more than USD 4.5 billion as of 2020 and is projected to expand at a CAGR more significant than 11.5 percent between 2021 to 2027.

The increasing prevalence of genetic disorders such as Edward syndrome Down’s syndrome, Patau syndrome, and more among newborns is the main reason for the growth behind the Prenatal and Newborn Genetic Testing Market. The increasing demand for detecting congenital anomalies in the prenatal and infant population contributes to the market’s growth. Furthermore, significant spending on research and intensive research in genomics and proteomics have led to substantial advancements in the field of technology.

Prenatal genetic testing is performed during pregnancy to assess the possibility of having a genetic condition or congenital disability affecting the fetus. The test is conducted to confirm the existence of genetic diseases like Tay-Sachs’s disease, sickle cell anemia, and down’s syndrome, among other conditions. Further screening is carried out when a baby is born, which is known as newborn genetic testing, to look for genetically-inherited diseases or congenital anomalies like the condition known as phenylketonuria (PKU) as well as muscular spinal atrophy, hereditary hearing loss, heart disease as well as other.

The genetic test for newborns and pregnant women is crucial in determining different options for pregnant women to improve the baby’s health for the newborn. The screening of newborns and pregnant women aids in the prevention of infant mortality and improves the outcomes for patients.

However, ethical concerns regarding prenatal and newborn testing could hinder the market’s progress. Genetic testing for newborns and prenatal poses ethical dilemmas and further impedes the development of services for clinical use and implementation of policies about access and financing. The use of screening for selective abortion has triggered a variety of issues. The increase in false-positive results during prenatal and newborn genetic tests may hinder the acceptance of genetic tests. About 5 percent of women are falsely positive during prenatal testing to detect Down syndrome.

prenatal and newborn genetic testing market

Get more information on this report : Download Free Sample Pages

Segments of prenatal and newborn genetic testing market 

Market, Based on Technology  (USD Million)

  • Screening
    • Non-invasive (NIPT)
    • Chorionic Villus Sampling (CVS)
    • Amniocentesis
    • Maternal Sulcer Screening (MSS)
    • Other
  • Diagnostic
    • mmPCR
    • Spectrophotometer
    • FISH
    • ASSAYS
    • Other

Market, by Disease (USD Million)

  • Down’s Syndrome
  • Phenylketonuria
  • Cystic Fibrosis
  • Sickle Cell Anaemia
  • Other

Market, By End-Use  (USD Million)

  • Hospital
  • Specialist and Maternity Clinics
  • Diagnostic Centers

Key Market Players

  • Bio-Rad Laboratories Inc.
  • F. Hoffmann La-Roche Ltd.
  • PerkinElmer, Inc.
  • Natera, Inc.
  • Agilent Technologies Inc.
  • Illumina, Inc.
  • Natera Inc.
  • Quest Diagnostics Incorporated
  • Others

Regional Analysis of Prenatal and Newborn Genetic Testing Market

  • North America
    • The U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • The Middle East and Africa
    • South Africa
    • Saudi Arabia
Report DetailsInformation
Base Year:2021
Prenatal genetic testing Statistics/ Market Size in 2020:USD 4,458.7 million
Forecast Period:2022-2030
The Forecast Period 2021-2027 CAGR:11.5%
The Value Projection for 2027:USD 9,541.8 million
Historical Data to:2016 through 2021
No. of Pages:198
Tables, Charts and Figures:268
Sessions covered:Technology, Diseases, End-Use and Region
Growth Factors
  • The technological advancements are bringing advantages in areas like prenatal screening and genetic screening for newborns
  • The prevalence of genetic disorders is increasing and chromosomal irregularities
  • Rising consanguineous relations
  • Prenatal screening and genetic screening for new-borns
  • Increase in the use of non-invasive Prenatal Testing
Pitfalls & Challenges:
  • The number of false results from prenatal tests
  • The absence of a modern infrastructure and skilled workers
  • Ethics concerns with prenatal tests and genetic screening of new-born babies

The COVID-19 virus has had little effect on the prenatal and newborn market of genetic tests. The coronavirus outbreak has afflicted millions of people around the globe and has caused a significant number of deaths. The government imposed lockdowns to prevent the spread of the virus, and emergencies were declared in most nations. The shutdown of critical industries of the economy caused distortions to the supply chain and slowed the movement of raw materials, further restricting the industry’s growth.

In the following years, the decline was in in-person visits for patients seeking prenatal and newborn genetic tests. According to a study by Cleveland Clinic Healthcare System, at the beginning of the 2020s, the COVID-19 virus caused a decline in the number of prenatal and newborn genetic tests.

Most participants in the study delayed the test procedure to avoid going to over-stressed healthcare facilities. A higher risk of COVID-19 infection during pregnancy could further limit the prenatal and newborn genetic testing procedure. However, the assistance provided by various public organizations to maintain the genetic testing of pregnant women and newborn babies could boost the market.

The increasing prevalence of genetic diseases and chromosomal irregularities will boost the worth of prenatal and newborn genetic testing market.

Genetic and chromosomal disorders have increased dramatically globally over the past few years. About 350 million suffer from rare and genetic diseases around the globe. According to the World Health Organization (WHO), diseases of the chromosome and genetic disorders are present in about 2 to five percent of live babies. These conditions account for approximately 30% of hospital visits and 50% of pediatric deaths in advanced economies. The rising prevalence of these diseases will increase the population targeted for the market, thus preventing industry growth.

Congenital and genetic disorders contribute to the burden of illness and lead to significant mortality among newborns and babies. Chromosomal anomalies are identified as one of the major causes of infant death across countries like the UAE, Bahrain, Oman, Kuwait, and Qatar. Several research studies in Saudi Arabia infer that majority of prenatal deaths were by congenital abnormalities. Additionally, genetic and chromosomal diseases cause several physical disabilities, including mental handicap blindness, deafness, and blindness.

In India, genetic disorders and chromosomal anomalies are shared among 25 to 60 per 1,000 births and are among the leading causes of infant death. Genetic causes can also increase the risk of multifactorial diseases and are the reason for growing inherited cardiovascular diseases in numerous nations. A rising number of chromosomal disorders, associated diseases, and genetic disorders will increase the prenatal and newborn genetic testing market during the forecast time frame.

prenatal and newborn genetic testing market

Customize this report as per your requirement

The advancements in technology for prenatal genetic screening will boost the market’s revenues.

The screening segment of the prenatal and newborn genetic testing market is expected to grow by an 11.4 percent growth rate until 2027, driven by technological advances, a surge in screening during pregnancy, and raising awareness of congenital disabilities. Screening tests are performed during pregnancy and after to detect congenitally and inherited congenital disabilities.

Pregnancy after 35 age raises the possibility of having an infant with chromosomal abnormalities, and the risk increases as you age. The increase in geriatric pregnancies will increase the need to accept screening tests for genetic disorders. The technological advancements in the genetic screening tests, such as non-invasive prenatal tests (NIPT), could further expand the  Prenatal and Newborn Genetic Testing Market industry’s size.

A high prevalence of Down’s disease will boost the Prenatal and Newborn Genetic Testing Market.

The segment of Down’s syndrome accounted for approximately 41 percent of the market in 2020 and is predicted to grow to 11.4 percent by 2027 due to the growing number of children with Down’s syndrome. Down’s syndrome is among the top chromosomal disorders linked to numerous congenital anomalies, leading to mental retardation and possibly grave health-related complications or defects. As per the World Health Organization, Down’s syndrome is present in one out of 1,100 to 1,000 live births across the globe.

In India, the condition is found for every child between 850 and 90 live births. Furthermore, according to the Centers for Diseases Control and Prevention (CDC), they have found that the incidence of this disease in recent years has increased by approximately 30 percent. The increasing rate of Down’s syndrome and the number of children affected by the condition will increase the demand for prenatal and newborn genetic testing market and help boost the industry’s income.

The Prenatal and Newborn Genetic Testing Market for the hospital segment was worth more than USD 2.1 billion in 2020, driven by the availability of modern technology for prenatal and newborn genetic testing and favorable reimbursement policies. Demand for health services is growing due to hospitals’ high utilization rate of genetic prenatal and newborn tests.

The increasing investment of government agencies in hospitals and the increasing numbers of skilled and skilled professionals are driving the demand in the industry. Furthermore, the preference for prenatal and newborn medical genetic testing is rising due to many hospital births and the accessibility of genetic tests for infants. Hospitals can provide genetic testing within the shortest period.

The U.S. dominated the North American prenatal and newborn genetic testing market in 2020 and is expected to grow 10.3 percent between 2021 and 2027. The largest share of revenue is due to various reasons, such as the prevalence of genetic diseases and the growing need for non-invasive tests for genetic disorders across the nation. According to the Centers for Disease Control and Prevention (CDC), approximately 6000 newborns across the U.S. are born with Down’s syndrome, affecting at least one in 700 babies.

prenatal and newborn genetic testing market

Interested in Any Specific Region or Country Level Data?

Strategies implemented by the major market players will help accelerate the expansion of the Prenatal and Newborn Genetic Testing Market  industry.

The major companies that operate in the prenatal and newborn market for genetic testing market include Ariosa Diagnostics (Roche), Berry Genomics, BGI, Biorad, Illumina, Laboratory Corporation of America, Natera, Qiagen, Sequenom, Trivitron Healthcare, and Verinata Health among other companies. They are a few of the significant players that focus on strategic initiatives, including partnerships, acquisitions, and acquisitions, as well as new products and commercialization to aid in the development of markets. Furthermore, these companies put money into research and development, which will allow them to launch new products that are innovative and generate maximum profits.

Research Approach/Methodology

MWR’s research methodology is based on extensive use of secondary and primary data sources. The research involves the analysis of various aspects impacting the Prenatal and Newborn Genetic Testing Market industry, including the policies of the government, the competitive landscape, the market environment and historical data, as well as current developments in the market technological innovation, emerging technologies, and the advancement of technology in related industries, and potential market risks as well as market barriers and issues.

Market Size Estimation of Prenatal and Newborn Genetic Testing Market 

Bottom-up and top-down approaches are employed to verify the size of the global product market and to estimate the size of the Prenatal and Newborn Genetic Testing Market for companies’ regions, regions segment as well as product segments and applications (end users). The market estimates are built on the product’s retail price (excluding discounts offered by the distributor, manufacturer, wholesaler, trader, or).

Partially splits, market shares and breakdown of product segments are calculated based on the weights allocated to each segment based on their usage rate and average sale price. The regional splits of the total product market and sub-segments are determined by the per cent of adoption or use of the particular product within the specific region or country.

Top key players of the Prenatal and Newborn Genetic Testing Market is determined through secondary data, and the market revenue is determined by secondary and primary approach. Secondary research comprised the study of financial and annual reports of the largest companies. In contrast, primary research involved extensive interviews with opinion makers and experts in the industry like experienced front-line employees, directors, CEOs, and marketing managers.

The market share, percentage splits and Growth Rate, as well as the market structure of the Prenatal and Newborn Genetic Testing Market, are calculated from secondary sources and then verified by primary sources. All potential factors that affect the markets are verified by conducting primary analysis, and then analyzed to obtain the final qualitative and quantitative results.

Market Breakdown, Data and Triangulation of Prenatal and Newborn Genetic Testing Market 

After completing market engineering, including calculations of market statistics, size estimations, forecasting of market breakdown, and data triangulation, a lot of analysis are then conducted to collect details and to confirm the numbers to be verified.

Throughout the entire method of market engineering, top-down and bottom-up methods are were widely used, together with a variety of triangulation techniques for market estimation and forecasting of market trends for the entire market segment and sub-segments . A thorough analysis of quantitative data is also carried out using all the data gathered during the entire market engineering process to present important information throughout the research.

Data Sources of Prenatal and Newborn Genetic Testing Market 

Secondary Sources

Secondary sources for Prenatal and Newborn Genetic Testing Market include annual reports, press releases, non-profit organizations and industry associations, government agencies, customs information, and others. This study focuses on extensive use of secondary sources, directories, databases, and directories like Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones and Company) and trading ECONOMICS and News Network, Statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS and company house documents CAS (American Chemical Society) and investor presentations along with SEC filings of corporations.

Secondary research are utilized to discover and gather details that could be used for a thorough technological, market-oriented and commercial analysis of the Prenatal and Newborn Genetic Testing Market. It also helps collecting necessary information on the most prominent companies, market classification and segmentation by market trends from the lowest level, and critical technological and market developments.

Primary Sources

For the research process, different sources from both the demand and supply sides are being interviewed to collect quantitative and qualitative information for Prenatal and Newborn Genetic Testing Market. The primary sources on the supply side comprise companies (and their rivals) and opinion leaders, experts from the industry and research institutes, distributors, traders and dealers, raw material suppliers and producers, etc.

The primary sources for demand-side information of Prenatal and Newborn Genetic Testing Market are industry experts, such as business leaders, sales and marketing directors, directors of innovation and technology supply chain executives, the market (product buyers) and top executives from a variety of key organizations and companies operating globally.

The primary studies are then conducted to find segments, types of segmentation, price ranges, application of the product important company, raw materials supply and demand downstream as well as the status of the industry and its forecast, and the fundamental market dynamics, such as risk factors, influence factors and opportunities obstacles to market entry, trends in the industry, and the strategies of key players.

COVID-19 impact Analysis of Prenatal and Newborn Genetic Testing Market 

To understand the impact of COVID, we must understand the supply chain of the industry and the value chain. By analysing the supply chain, we understand the bottlenecks affecting the industry’s growth. And by analysing the value chain, we understand what value each component adds to the entire industry. We then try to understand the COVID impact has on the industry by trying to find answers to the following questions: 

How many jobs have been lost?

How many people have died due to COVID?

How did the Government respond, and what measures Government has taken to revive a particular industry?

How companies have responded to COVID?

What growth rate companies are expecting?

We also analyse their annual reports and press releases to understand their
strategies post COVID. Then we move towards the primary research part and contact government officials and industry experts such as CEOs, COOs, Directors, VPs, Directors and Managers to understand what impact COVID has had on their businesses and what they are doing to cope with it.

We also try to understand their views regarding other financial aspects, such as recovery and obstacles in achieving pre-COVID growth and when they expect to achieve it.

Finally, after gathering the info from secondary and primary research, we try to form a model through which we gauge the COVID impact on a particular industry (Prenatal and Newborn Genetic Testing Market).

Other MWR Trending Report

Cystic fibrosis drug market 

Honey Powder Market

Table of Content

Chapter 1   Methodology

1.1    Market definition

1.2    Base estimates and working

1.3    Forecast parameters

1.4    Data validation

1.5    Data sources

1.5.1    Secondary

1.5.1.1    Paid sources

1.5.1.2    Unpaid sources

1.5.2    Primary

Chapter 2   Executive Summary

2.1    Prenatal and new-born genetic testing industry 3600 synopsis, 2016 – 2027

2.1.1    Business trends

2.1.2    Technology trends

2.1.3    Disease trends

2.1.4    End-use trends

2.1.5    Regional trends

Chapter 3   Prenatal and New-born Genetic Testing Industry Insights

3.1    Industry segmentation

3.2    Industry landscape, 2016 – 2027 (USD Million)

3.3    Industry impact factors

3.3.1    Growth drivers

3.3.1.1    Technological advancements and increasing benefits in the field of prenatal testing and new-born genetic screening

3.3.1.2    Increasing prevalence of genetic disorders and chromosomal abnormalities

3.3.1.3    Rising consanguineous relations

3.3.1.4    Government initiatives and support for prenatal testing and new-born genetic screening

3.3.1.5    Rise in adoption of Non-invasive Prenatal Testing

3.3.2    Industry pitfalls and challenges

3.3.2.1    Increasing false results for prenatal tests

3.3.2.2    Lack of advanced infrastructure and skilled labor

3.3.2.3    Ethical issues to prenatal testing and new-born genetic screening

3.4    Growth potential analysis

3.4.1    By technology

3.4.2    By disease

3.4.3    By end-use

3.5    COVID-19 impact analysis

3.6    Regulatory landscape

3.6.1    U.S.

3.6.2    Europe

3.7    Porter’s analysis

3.8    Competitive landscape, 2020

3.8.1    Company matrix analysis, 2020

3.9    PESTEL analysis

Chapter 4   Prenatal and New-born Genetic Testing Market, By Technology

4.1    Key segment trends

4.2    Screening

4.2.1    Market size, by region, 2016 – 2027 (USD Million)

4.2.2    Chorionic Villus Sampling

4.2.2.1    Market size, by region, 2016 – 2027 (USD Million)

4.2.3    Maternal Serum Screening

4.2.3.1    Market size, by region, 2016 – 2027 (USD Million)

4.2.4    Amniocentesis

4.2.4.1    Market size, by region, 2016 – 2027 (USD Million)

4.2.5    Non-invasive Prenatal Testing

4.2.5.1    Market size, by region, 2016 – 2027 (USD Million)

4.2.6    Others

4.2.6.1    Market size, by region, 2016 – 2027 (USD Million)

4.3    Diagnostic

4.3.1    Market size, by region, 2016 – 2027 (USD Million)

4.3.2    mmPCR

4.3.2.1    Market size, by region, 2016 – 2027 (USD Million)

4.3.3    Spectrophotometer

4.3.3.1    Market size, by region, 2016 – 2027 (USD Million)

4.3.4    FISH

4.3.4.1    Market size, by region, 2016 – 2027 (USD Million)

4.3.5    Assays

4.3.5.1    Market size, by region, 2016 – 2027 (USD Million)

4.3.6    Others

4.3.6.1    Market size, by region, 2016 – 2027 (USD Million)

Chapter 5   Prenatal and New-born Genetic Testing Market, By Disease

5.1    Key segment trends

5.2    Down’s Syndrome

5.2.1    Market size, by region, 2016 – 2027 (USD Million)

5.3    Phenylketonuria

5.3.1    Market size, by region, 2016 – 2027 (USD Million)

5.4    Cystic Fibrosis

5.4.1    Market size, by region, 2016 – 2027 (USD Million)

5.5    Sickle Cell Anaemia

5.5.1    Market size, by region, 2016 – 2027 (USD Million)

5.6    Others

5.6.1    Market size, by region, 2016 – 2027 (USD Million)

Chapter 6   Prenatal and New-born Genetic Testing Market, By End-use

6.1    Key segment trends

6.2    Hospitals

6.2.1    Market size, by region, 2016 – 2027 (USD Million)

6.3    Maternity and Specialty Clinics

6.3.1    Market size, by region, 2016 – 2027 (USD Million)

6.4    Diagnostic Centers

6.4.1    Market size, by region, 2016 – 2027 (USD Million)

Chapter 7   Prenatal and New-born Genetic Testing Market, By Region

7.1    Key regional trends

7.2    North America

7.2.1    Market size, by country, 2016 – 2027 (USD Million)

7.2.2    Market size, by technology, 2016 – 2027 (USD Million)

7.2.2.1    Market size, by screening, 2016 – 2027 (USD Million)

7.2.2.2    Market size, by diagnostic, 2016 – 2027 (USD Million)

7.2.3    Market size, by disease, 2016 – 2027 (USD Million)

7.2.4    Market size, by end-use, 2016 – 2027 (USD Million)

7.2.5    U.S.

7.2.5.1    Market size, by technology, 2016 – 2027 (USD Million)

7.2.5.1.1    Market size, by screening, 2016 – 2027 (USD Million)

7.2.5.1.2    Market size, by diagnostic, 2016 – 2027 (USD Million)

7.2.5.2    Market size, by disease, 2016 – 2027 (USD Million)

7.2.5.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.2.6    Canada

7.2.6.1    Market size, by technology, 2016 – 2027 (USD Million)

7.2.6.1.1    Market size, by screening, 2016 – 2027 (USD Million)

7.2.6.1.2    Market size, by diagnostic, 2016 – 2027 (USD Million)

7.2.6.2    Market size, by disease, 2016 – 2027 (USD Million)

7.2.6.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.3    Europe

7.3.1    Market size, by country, 2016 – 2027 (USD Million)

7.3.2    Market size, by technology, 2016 – 2027 (USD Million)

7.3.2.1    Market size, by screening, 2016 – 2027 (USD Million)

7.3.2.2    Market size, by diagnostic, 2016 – 2027 (USD Million)

7.3.3    Market size, by disease, 2016 – 2027 (USD Million)

7.3.4    Market size, by end-use, 2016 – 2027 (USD Million)

7.3.5    Germany

7.3.5.1    Market size, by technology, 2016 – 2027 (USD Million)

7.3.5.1.1    Market size, by screening, 2016 – 2027 (USD Million)

7.3.5.1.2    Market size, by diagnostic, 2016 – 2027 (USD Million)

7.3.5.2    Market size, by disease, 2016 – 2027 (USD Million)

7.3.5.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.3.6    UK

7.3.6.1    Market size, by technology, 2016 – 2027 (USD Million)

7.3.6.1.1    Market size, by screening, 2016 – 2027 (USD Million)

7.3.6.1.2    Market size, by diagnostic, 2016 – 2027 (USD Million)

7.3.6.2    Market size, by disease, 2016 – 2027 (USD Million)

7.3.6.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.3.7    France

7.3.7.1    Market size, by technology, 2016 – 2027 (USD Million)

7.3.7.1.1    Market size, by screening, 2016 – 2027 (USD Million)

7.3.7.1.2    Market size, by diagnostic, 2016 – 2027 (USD Million)

7.3.7.2    Market size, by disease, 2016 – 2027 (USD Million)

7.3.7.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.3.8    Italy

7.3.8.1    Market size, by technology, 2016 – 2027 (USD Million)

7.3.8.1.1    Market size, by screening, 2016 – 2027 (USD Million)

7.3.8.1.2    Market size, by diagnostic, 2016 – 2027 (USD Million)

7.3.8.2    Market size, by disease, 2016 – 2027 (USD Million)

7.3.8.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.3.9    Spain

7.3.9.1    Market size, by technology, 2016 – 2027 (USD Million)

7.3.9.1.1    Market size, by screening, 2016 – 2027 (USD Million)

7.3.9.1.2    Market size, by diagnostic, 2016 – 2027 (USD Million)

7.3.9.2    Market size, by disease, 2016 – 2027 (USD Million)

7.3.9.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.4    Asia Pacific

7.4.1    Market size, by country, 2016 – 2027 (USD Million)

7.4.2    Market size, by technology, 2016 – 2027 (USD Million)

7.4.2.1    Market size, by screening, 2016 – 2027 (USD Million)

7.4.2.2    Market size, by diagnostic, 2016 – 2027 (USD Million)

7.4.3    Market size, by disease, 2016 – 2027 (USD Million)

7.4.4    Market size, by end-use, 2016 – 2027 (USD Million)

7.4.5    China

7.4.5.1    Market size, by technology, 2016 – 2027 (USD Million)

7.4.5.1.1    Market size, by screening, 2016 – 2027 (USD Million)

7.4.5.1.2    Market size, by diagnostic, 2016 – 2027 (USD Million)

7.4.5.2    Market size, by disease, 2016 – 2027 (USD Million)

7.4.5.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.4.6    India

7.4.6.1    Market size, by technology, 2016 – 2027 (USD Million)

7.4.6.1.1    Market size, by screening, 2016 – 2027 (USD Million)

7.4.6.1.2    Market size, by diagnostic, 2016 – 2027 (USD Million)

7.4.6.2    Market size, by disease, 2016 – 2027 (USD Million)

7.4.6.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.4.7    Japan

7.4.7.1    Market size, by technology, 2016 – 2027 (USD Million)

7.4.7.1.1    Market size, by screening, 2016 – 2027 (USD Million)

7.4.7.1.2    Market size, by diagnostic, 2016 – 2027 (USD Million)

7.4.7.2    Market size, by disease, 2016 – 2027 (USD Million)

7.4.7.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.4.8    Australia

7.4.8.1    Market size, by technology, 2016 – 2027 (USD Million)

7.4.8.1.1    Market size, by screening, 2016 – 2027 (USD Million)

7.4.8.1.2    Market size, by diagnostic, 2016 – 2027 (USD Million)

7.4.8.2    Market size, by disease, 2016 – 2027 (USD Million)

7.4.8.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.5    Latin America

7.5.1    Market size, by country, 2016 – 2027 (USD Million)

7.5.2    Market size, by technology, 2016 – 2027 (USD Million)

7.5.2.1    Market size, by screening, 2016 – 2027 (USD Million)

7.5.2.2    Market size, by diagnostic, 2016 – 2027 (USD Million)

7.5.3    Market size, by disease, 2016 – 2027 (USD Million)

7.5.4    Market size, by end-use, 2016 – 2027 (USD Million)

7.5.5    Brazil

7.5.5.1    Market size, by technology, 2016 – 2027 (USD Million)

7.5.5.1.1    Market size, by screening, 2016 – 2027 (USD Million)

7.5.5.1.2    Market size, by diagnostic, 2016 – 2027 (USD Million)

7.5.5.2    Market size, by disease, 2016 – 2027 (USD Million)

7.5.5.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.5.6    Mexico

7.5.6.1    Market size, by technology, 2016 – 2027 (USD Million)

7.5.6.1.1    Market size, by screening, 2016 – 2027 (USD Million)

7.5.6.1.2    Market size, by diagnostic, 2016 – 2027 (USD Million)

7.5.6.2    Market size, by disease, 2016 – 2027 (USD Million)

7.5.6.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.5.7    Argentina

7.5.7.1    Market size, by technology, 2016 – 2027 (USD Million)

7.5.7.1.1    Market size, by screening, 2016 – 2027 (USD Million)

7.5.7.1.2    Market size, by diagnostic, 2016 – 2027 (USD Million)

7.5.7.2    Market size, by disease, 2016 – 2027 (USD Million)

7.5.7.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.6    Middle East and Africa

7.6.1    Market size, by country, 2016 – 2027 (USD Million)

7.6.2    Market size, by technology, 2016 – 2027 (USD Million)

7.6.2.1    Market size, by screening, 2016 – 2027 (USD Million)

7.6.2.2    Market size, by diagnostic, 2016 – 2027 (USD Million)

7.6.3    Market size, by disease, 2016 – 2027 (USD Million)

7.6.4    Market size, by end-use, 2016 – 2027 (USD Million)

7.6.5    South Africa

7.6.5.1    Market size, by technology, 2016 – 2027 (USD Million)

7.6.5.1.1    Market size, by screening, 2016 – 2027 (USD Million)

7.6.5.1.2    Market size, by diagnostic, 2016 – 2027 (USD Million)

7.6.5.2    Market size, by disease, 2016 – 2027 (USD Million)

7.6.5.3    Market size, by end-use, 2016 – 2027 (USD Million)

7.6.6    Saudi Arabia

7.6.6.1    Market size, by technology, 2016 – 2027 (USD Million)

7.6.6.1.1    Market size, by screening, 2016 – 2027 (USD Million)

7.6.6.1.2    Market size, by diagnostic, 2016 – 2027 (USD Million)

7.6.6.2    Market size, by disease, 2016 – 2027 (USD Million)

7.6.6.3    Market size, by end-use, 2016 – 2027 (USD Million)

Chapter 8   Company Profiles

8.1    Competitive dashboard, 2020

8.2    Abbott

8.2.1    Business overview

8.2.2    Financial data

8.2.3    Technology landscape

8.2.4    Strategic outlook

8.2.5    SWOT analysis

8.3    Agilent

8.3.1    Business overview

8.3.2    Financial data

8.3.3    Technology landscape

8.3.4    Strategic outlook

8.3.5    SWOT analysis

8.4    AutoGenomics

8.4.1    Business overview

8.4.2    Financial data

8.4.3    Technology landscape

8.4.4    Strategic outlook

8.4.5    SWOT analysis

8.5    Ariosa Diagnostics

8.5.1    Business overview

8.5.2    Financial data

8.5.3    Technology landscape

8.5.4    Strategic outlook

8.5.5    SWOT analysis

8.6    Baebies

8.6.1    Business overview

8.6.2    Financial data

8.6.3    Technology landscape

8.6.4    Strategic outlook

8.6.5    SWOT analysis

8.7    Berry Genomics Co. Ltd

8.7.1    Business overview

8.7.2    Financial data

8.7.3    Technology landscape

8.7.4    Strategic outlook

8.7.5    SWOT analysis

8.8    BGI

8.8.1    Business overview

8.8.2    Financial data

8.8.3    Technology landscape

8.8.4    Strategic outlook

8.8.5    SWOT analysis

8.9    Biocartis Group NV

8.9.1    Business overview

8.9.2    Financial data

8.9.3    Technology landscape

8.9.4    Strategic outlook

8.9.5    SWOT analysis

8.10    Bio-Rad Laboratories, Inc.

8.10.1    Business overview

8.10.2    Financial data

8.10.3    Technology landscape

8.10.4    Strategic outlook

8.10.5    SWOT analysis

8.11    Illumina, Inc

8.11.1    Business overview

8.11.2    Financial data

8.11.3    Technology landscape

8.11.4    Strategic outlook

8.11.5    SWOT analysis

8.12    Laboratory Corporation of America

8.12.1    Business overview

8.12.2    Financial data

8.12.3    Technology landscape

8.12.4    Strategic outlook

8.12.5    SWOT analysis

8.13    Masimo Corporation

8.13.1    Business overview

8.13.2    Financial data

8.13.3    Technology landscape

8.13.4    Strategic outlook

8.13.5    SWOT analysis

8.14    Natera, Inc.

8.14.1    Business overview

8.14.2    Financial data

8.14.3    Technology landscape

8.14.4    Strategic outlook

8.14.5    SWOT analysis

8.15    PerkinElmer, Inc

8.15.1    Business overview

8.15.2    Financial data

8.15.3    Technology landscape

8.15.4    Strategic outlook

8.15.5    SWOT analysis

8.16    Progenity, Inc.

8.16.1    Business overview

8.16.2    Financial data

8.16.3    Technology landscape

8.16.4    Strategic outlook

8.16.5    SWOT analysis

8.17    Qiagen

8.17.1    Business overview

8.17.2    Financial data

8.17.3    Technology landscape

8.17.4    Strategic outlook

8.17.5    SWOT analysis

8.18    Sequenom, Inc.

8.18.1    Business overview

8.18.2    Financial data

8.18.3    Technology landscape

8.18.4    Strategic outlook

8.18.5    SWOT analysis

8.19    Trivitron Healthcare Private Limited

8.19.1    Business overview

8.19.2    Financial data

8.19.3    Technology landscape

8.19.4    Strategic outlook

8.19.5    SWOT analysis

Data Tables

TABLE 1.    Prenatal and new-born genetic testing industry 3600 synopsis, 2016–2027

TABLE 2.    Global prenatal and new-born genetic testing market, 2016 – 2020 (USD Million)

TABLE 3.    Global prenatal and new-born genetic testing market, 2021 – 2027 (USD Million)

TABLE 4.    Global prenatal and new-born genetic testing market, by technology, 2016 – 2020 (USD Million)

TABLE 5.    Global prenatal and new-born genetic testing market, by technology, 2021 – 2027 (USD Million)

TABLE 6.    Global prenatal and new-born genetic testing market, by disease, 2016 – 2020 (USD Million)

TABLE 7.    Global prenatal and new-born genetic testing market, by disease, 2021 – 2027 (USD Million)

TABLE 8.    Global prenatal and new-born genetic testing market, by end–use, 2016 – 2020 (USD Million)

TABLE 9.    Global prenatal and new-born genetic testing market, by end–use, 2021 – 2027 (USD Million)

TABLE 10.  Global prenatal and new-born genetic testing market, by region, 2016 – 2020 (USD Million)

TABLE 11.  Global prenatal and new-born genetic testing market, by region, 2021 – 2027 (USD Million)

TABLE 12.  Industry impact forces

TABLE 13.  Screening market size, by region, 2016 – 2020 (USD Million)

TABLE 14.  Screening market size, by region, 2021 – 2027 (USD Million)

TABLE 15.  Chorionic villus sampling market size, by region, 2016 – 2020 (USD Million)

TABLE 16.  Chorionic villus sampling market size, by region, 2021 – 2027 (USD Million)

TABLE 17.  Maternal serum screening market size, by region, 2016 – 2020 (USD Million)

TABLE 18.  Maternal serum screening market size, by region, 2021 – 2027 (USD Million)

TABLE 19.  Amniocentesis market size, by region, 2016 – 2020 (USD Million)

TABLE 20.  Amniocentesis market size, by region, 2021 – 2027 (USD Million)

TABLE 21.  Non–invasive prenatal testing market size, by region, 2016 – 2020 (USD Million)

TABLE 22.  Non–invasive prenatal testing market size, by region, 2021 – 2027 (USD Million)

TABLE 23.  Others market size, by region, 2016 – 2020 (USD Million)

TABLE 24.  Others market size, by region, 2021 – 2027 (USD Million)

TABLE 25.  Diagnostic market size, by region, 2016 – 2020 (USD Million)

TABLE 26.  Diagnostic market size, by region, 2021 – 2027 (USD Million)

TABLE 27.  mmPCR market size, by region, 2016 – 2020 (USD Million)

TABLE 28.  mmPCR market size, by region, 2021 – 2027 (USD Million)

TABLE 29.  Spectrophotometer market size, by region, 2016 – 2020 (USD Million)

TABLE 30.  Spectrophotometer market size, by region, 2021 – 2027 (USD Million)

TABLE 31.  FISH market size, by region, 2016 – 2020 (USD Million)

TABLE 32.  FISH market size, by region, 2021 – 2027 (USD Million)

TABLE 33.  Assays market size, by region, 2016 – 2020 (USD Million)

TABLE 34.  Assays market size, by region, 2021 – 2027 (USD Million)

TABLE 35.  Others market size, by region, 2016 – 2020 (USD Million)

TABLE 36.  Others market size, by region, 2021 – 2027 (USD Million)

TABLE 37.  Down’s syndrome market size, by region, 2016 – 2020 (USD Million)

TABLE 38.  Down’s syndrome market size, by region, 2021 – 2027 (USD Million)

TABLE 39.  Phenylketonuria market size, by region, 2016 – 2020 (USD Million)

TABLE 40.  Phenylketonuria market size, by region, 2021 – 2027 (USD Million)

TABLE 41.  Cystic fibrosis market size, by region, 2016 – 2020 (USD Million)

TABLE 42.  Cystic fibrosis market size, by region, 2021 – 2027 (USD Million)

TABLE 43.  Sickle cell anaemia market size, by region, 2016 – 2020 (USD Million)

TABLE 44.  Sickle cell anaemia market size, by region, 2021 – 2027 (USD Million)

TABLE 45.  Others market size, by region, 2016 – 2020 (USD Million)

TABLE 46.  Others market size, by region, 2021 – 2027 (USD Million)

TABLE 47.  Hospitals market size, by region, 2015 – 2019 (USD Million)

TABLE 48.  Hospitals market size, by region, 2020 – 2026 (USD Million)

TABLE 49.  Maternity and specialty clinics market size, by region, 2015 – 2019 (USD Million)

TABLE 50.  Maternity and specialty clinics market size, by region, 2020 – 2026 (USD Million)

TABLE 51.  Diagnostic centers market size, by region, 2015 – 2019 (USD Million)

TABLE 52.  Diagnostic centers market size, by region, 2020 – 2026 (USD Million)

TABLE 53.  North America prenatal and new-born genetic testing market size, by country, 2016 – 2020 (USD Million)

TABLE 54.  North America prenatal and new-born genetic testing market size, by country, 2021 – 2027 (USD Million)

TABLE 55.  North America prenatal and new-born genetic testing market size, by technology, 2016 – 2020 (USD Million)

TABLE 56.  North America prenatal and new-born genetic testing market size, by technology, 2021 – 2027 (USD Million)

TABLE 57.  North America prenatal and new-born genetic testing market size, by screening, 2016 – 2020 (USD Million)

TABLE 58.  North America prenatal and new-born genetic testing market size, by screening, 2021 – 2027 (USD Million)

TABLE 59.  North America prenatal and new-born genetic testing market size, by diagnostics, 2016 – 2020 (USD Million)

TABLE 60.  North America prenatal and new-born genetic testing market size, by diagnostics, 2021 – 2027 (USD Million)

TABLE 61.  North America prenatal and new-born genetic testing market size, by disease, 2016 – 2020 (USD Million)

TABLE 62.  North America prenatal and new-born genetic testing market size, by disease, 2021 – 2027 (USD Million)

TABLE 63.  North America prenatal and new-born genetic testing market size, by end–use, 2016 – 2020 (USD Million)

TABLE 64.  North America prenatal and new-born genetic testing market size, by end–use, 2021 – 2027 (USD Million)

TABLE 65.  U.S. prenatal and new-born genetic testing market size, by technology, 2016 – 2020 (USD Million)

TABLE 66.  U.S. prenatal and new-born genetic testing market size, by technology, 2021 – 2027 (USD Million)

TABLE 67.  U.S. prenatal and new-born genetic testing market size, by screening, 2016 – 2020 (USD Million)

TABLE 68.  U.S. prenatal and new-born genetic testing market size, by screening, 2021 – 2027 (USD Million)

TABLE 69.  U.S. prenatal and new-born genetic testing market size, by diagnostic, 2016 – 2020 (USD Million)

TABLE 70.  U.S. prenatal and new-born genetic testing market size, by diagnostic, 2021 – 2027 (USD Million)

TABLE 71.  U.S. prenatal and new-born genetic testing market size, by disease, 2016 – 2020 (USD Million)

TABLE 72.  U.S. prenatal and new-born genetic testing market size, by disease, 2021 – 2027 (USD Million)

TABLE 73.  U.S. prenatal and new-born genetic testing market size, by end–use, 2016 – 2020 (USD Million)

TABLE 74.  U.S. prenatal and new-born genetic testing market size, by end–use, 2021 – 2027 (USD Million)

TABLE 75.  Canada prenatal and new-born genetic testing market size, by technology, 2016 – 2020 (USD Million)

TABLE 76.  Canada prenatal and new-born genetic testing market size, by technology, 2021 – 2027 (USD Million)

TABLE 77.  Canada prenatal and new-born genetic testing market size, by screening, 2016 – 2020 (USD Million)

TABLE 78.  Canada prenatal and new-born genetic testing market size, by screening, 2021 – 2027 (USD Million)

TABLE 79.  Canada prenatal and new-born genetic testing market size, by diagnostic, 2016 – 2020 (USD Million)

TABLE 80.  Canada prenatal and new-born genetic testing market size, by diagnostic, 2021 – 2027 (USD Million)

TABLE 81.  Canada prenatal and new-born genetic testing market size, by disease, 2016 – 2020 (USD Million)

TABLE 82.  Canada prenatal and new-born genetic testing market size, by disease, 2021 – 2027 (USD Million)

TABLE 83.  Canada prenatal and new-born genetic testing market size, by end–use, 2016 – 2020 (USD Million)

TABLE 84.  Canada prenatal and new-born genetic testing market size, by end–use, 2021 – 2027 (USD Million)

TABLE 85.  Europe prenatal and new-born genetic testing market size, by country, 2016 – 2020 (USD Million)

TABLE 86.  Europe prenatal and new-born genetic testing market size, by country, 2021 – 2027 (USD Million)

TABLE 87.  Europe prenatal and new-born genetic testing market size, by technology, 2016 – 2020 (USD Million)

TABLE 88.  Europe prenatal and new-born genetic testing market size, by technology, 2021 – 2027 (USD Million)

TABLE 89.  Europe prenatal and new-born genetic testing market size, by screening, 2016 – 2020 (USD Million)

TABLE 90.  Europe prenatal and new-born genetic testing market size, by screening, 2021 – 2027 (USD Million)

TABLE 91.  Europe prenatal and new-born genetic testing market size, by diagnostic, 2016 – 2020 (USD Million)

TABLE 92.  Europe prenatal and new-born genetic testing market size, by diagnostic, 2021 – 2027 (USD Million)

TABLE 93.  Europe prenatal and new-born genetic testing market size, by disease, 2016 – 2020 (USD Million)

TABLE 94.  Europe prenatal and new-born genetic testing market size, by disease, 2021 – 2027 (USD Million)

TABLE 95.  Europe prenatal and new-born genetic testing market size, by end–use, 2016 – 2020 (USD Million)

TABLE 96.  Europe prenatal and new-born genetic testing market size, by end–use, 2021 – 2027 (USD Million)

TABLE 97.  Germany prenatal and new-born genetic testing market size, by technology, 2016 – 2020 (USD Million)

TABLE 98.  Germany prenatal and new-born genetic testing market size, by technology, 2021 – 2027 (USD Million)

TABLE 99.  Germany prenatal and new-born genetic testing market size, by screening, 2016 – 2020 (USD Million)

TABLE 100.  Germany prenatal and new-born genetic testing market size, by screening, 2021 – 2027 (USD Million)

TABLE 101.  Germany prenatal and new-born genetic testing market size, by diagnostic, 2016 – 2020 (USD Million)

TABLE 102.  Germany prenatal and new-born genetic testing market size, by diagnostic, 2021 – 2027 (USD Million)

TABLE 103.  Germany prenatal and new-born genetic testing market size, by disease, 2016 – 2020 (USD Million)

TABLE 104.  Germany prenatal and new-born genetic testing market size, by disease, 2021 – 2027 (USD Million)

TABLE 105.  Germany prenatal and new-born genetic testing market size, by end–use, 2016 – 2020 (USD Million)

TABLE 106.  Germany prenatal and new-born genetic testing market size, by end–use, 2021 – 2027 (USD Million)

TABLE 107.  UK prenatal and new-born genetic testing market size, by technology, 2016 – 2020 (USD Million)

TABLE 108.  UK prenatal and new-born genetic testing market size, by technology, 2021 – 2027 (USD Million)

TABLE 109.  UK prenatal and new-born genetic testing market size, by screening, 2016 – 2020 (USD Million)

TABLE 110.  UK prenatal and new-born genetic testing market size, by screening, 2021 – 2027 (USD Million)

TABLE 111.  UK prenatal and new-born genetic testing market size, by diagnostic, 2016 – 2020 (USD Million)

TABLE 112.  UK prenatal and new-born genetic testing market size, by diagnostic, 2021 – 2027 (USD Million)

TABLE 113.  UK prenatal and new-born genetic testing market size, by disease, 2016 – 2020 (USD Million)

TABLE 114.  UK prenatal and new-born genetic testing market size, by disease, 2021 – 2027 (USD Million)

TABLE 115.  UK prenatal and new-born genetic testing market size, by end–use, 2016 – 2020 (USD Million)

TABLE 116.  UK prenatal and new-born genetic testing market size, by end–use, 2021 – 2027 (USD Million)

TABLE 117.  France prenatal and new-born genetic testing market size, by technology, 2016 – 2020 (USD Million)

TABLE 118.  France prenatal and new-born genetic testing market size, by technology, 2021 – 2027 (USD Million)

TABLE 119.  France prenatal and new-born genetic testing market size, by screening, 2016 – 2020 (USD Million)

TABLE 120.  France prenatal and new-born genetic testing market size, by screening, 2021 – 2027 (USD Million)

TABLE 121.  France prenatal and new-born genetic testing market size, by diagnostic, 2016 – 2020 (USD Million)

TABLE 122.  France prenatal and new-born genetic testing market size, by diagnostic, 2021 – 2027 (USD Million)

TABLE 123.  France prenatal and new-born genetic testing market size, by disease, 2016 – 2020 (USD Million)

TABLE 124.  France prenatal and new-born genetic testing market size, by disease, 2021 – 2027 (USD Million)

TABLE 125.  France prenatal and new-born genetic testing market size, by end–use, 2016 – 2020 (USD Million)

TABLE 126.  France prenatal and new-born genetic testing market size, by end–use, 2021 – 2027 (USD Million)

TABLE 127.  Italy prenatal and new-born genetic testing market size, by technology, 2016 – 2020 (USD Million)

TABLE 128.  Italy prenatal and new-born genetic testing market size, by technology, 2021 – 2027 (USD Million)

TABLE 129.  Italy prenatal and new-born genetic testing market size, by screening, 2016 – 2020 (USD Million)

TABLE 130.  Italy prenatal and new-born genetic testing market size, by screening, 2021 – 2027 (USD Million)

TABLE 131.  Italy prenatal and new-born genetic testing market size, by diagnostic, 2016 – 2020 (USD Million)

TABLE 132.  Italy prenatal and new-born genetic testing market size, by diagnostic, 2021 – 2027 (USD Million)

TABLE 133.  Italy prenatal and new-born genetic testing market size, by disease, 2016 – 2020 (USD Million)

TABLE 134.  Italy prenatal and new-born genetic testing market size, by disease, 2021 – 2027 (USD Million)

TABLE 135.  Italy prenatal and new-born genetic testing market size, by end–use, 2016 – 2020 (USD Million)

TABLE 136.  Italy prenatal and new-born genetic testing market size, by end–use, 2021 – 2027 (USD Million)

TABLE 137.  Spain prenatal and new-born genetic testing market size, by technology, 2016 – 2020 (USD Million)

TABLE 138.  Spain prenatal and new-born genetic testing market size, by technology, 2021 – 2027 (USD Million)

TABLE 139.  Spain prenatal and new-born genetic testing market size, by screening, 2016 – 2020 (USD Million)

TABLE 140.  Spain prenatal and new-born genetic testing market size, by screening, 2021 – 2027 (USD Million)

TABLE 141.  Spain prenatal and new-born genetic testing market size, by diagnostic, 2016 – 2020 (USD Million)

TABLE 142.  Spain prenatal and new-born genetic testing market size, by diagnostic, 2021 – 2027 (USD Million)

TABLE 143.  Spain prenatal and new-born genetic testing market size, by disease, 2016 – 2020 (USD Million)

TABLE 144.  Spain prenatal and new-born genetic testing market size, by disease, 2021 – 2027 (USD Million)

TABLE 145.  Spain prenatal and new-born genetic testing market size, by end–use, 2016 – 2020 (USD Million)

TABLE 146.  Spain prenatal and new-born genetic testing market size, by end–use, 2021 – 2027 (USD Million)

TABLE 147.  Asia Pacific prenatal and new-born genetic testing market size, by country, 2016 – 2020 (USD Million)

TABLE 148.  Asia Pacific prenatal and new-born genetic testing market size, by country, 2021 – 2027 (USD Million)

TABLE 149.  Asia Pacific prenatal and new-born genetic testing market size, by technology, 2016 – 2020 (USD Million)

TABLE 150.  Asia Pacific prenatal and new-born genetic testing market size, by technology, 2021 – 2027 (USD Million)

TABLE 151.  Asia Pacific prenatal and new-born genetic testing market size, by screening, 2016 – 2020 (USD Million)

TABLE 152.  Asia Pacific prenatal and new-born genetic testing market size, by screening, 2021 – 2027 (USD Million)

TABLE 153.  Asia Pacific prenatal and new-born genetic testing market size, by diagnostic, 2016 – 2020 (USD Million)

TABLE 154.  Asia Pacific prenatal and new-born genetic testing market size, by diagnostic, 2021 – 2027 (USD Million)

TABLE 155.  Asia Pacific prenatal and new-born genetic testing market size, by disease, 2016 – 2020 (USD Million)

TABLE 156.  Asia Pacific prenatal and new-born genetic testing market size, by disease, 2021 – 2027 (USD Million)

TABLE 157.  Asia Pacific prenatal and new-born genetic testing market size, by end–use, 2016 – 2020 (USD Million)

TABLE 158.  Asia Pacific prenatal and new-born genetic testing market size, by end–use, 2021 – 2027 (USD Million)

TABLE 159.  China prenatal and new-born genetic testing market size, by technology, 2016 – 2020 (USD Million)

TABLE 160.  China prenatal and new-born genetic testing market size, by technology, 2021 – 2027 (USD Million)

TABLE 161.  China prenatal and new-born genetic testing market size, by screening, 2016 – 2020 (USD Million)

TABLE 162.  China prenatal and new-born genetic testing market size, by screening, 2021 – 2027 (USD Million)

TABLE 163.  China prenatal and new-born genetic testing market size, by diagnostic, 2016 – 2020 (USD Million)

TABLE 164.  China prenatal and new-born genetic testing market size, by diagnostic, 2021 – 2027 (USD Million)

TABLE 165.  China prenatal and new-born genetic testing market size, by disease, 2016 – 2020 (USD Million)

TABLE 166.  China prenatal and new-born genetic testing market size, by disease, 2021 – 2027 (USD Million)

TABLE 167.  China prenatal and new-born genetic testing market size, by end–use, 2016 – 2020 (USD Million)

TABLE 168.  China prenatal and new-born genetic testing market size, by end–use, 2021 – 2027 (USD Million)

TABLE 169.  India prenatal and new-born genetic testing market size, by technology, 2016 – 2020 (USD Million)

TABLE 170.  India prenatal and new-born genetic testing market size, by technology, 2021 – 2027 (USD Million)

TABLE 171.  India prenatal and new-born genetic testing market size, by screening, 2016 – 2020 (USD Million)

TABLE 172.  India prenatal and new-born genetic testing market size, by screening, 2021 – 2027 (USD Million)

TABLE 173.  India prenatal and new-born genetic testing market size, by diagnostic, 2016 – 2020 (USD Million)

TABLE 174.  India prenatal and new-born genetic testing market size, by diagnostic, 2021 – 2027 (USD Million)

TABLE 175.  India prenatal and new-born genetic testing market size, by disease, 2016 – 2020 (USD Million)

TABLE 176.  India prenatal and new-born genetic testing market size, by disease, 2021 – 2027 (USD Million)

TABLE 177.  India prenatal and new-born genetic testing market size, by end–use, 2016 – 2020 (USD Million)

TABLE 178.  India prenatal and new-born genetic testing market size, by end–use, 2021 – 2027 (USD Million)

TABLE 179.  Japan prenatal and new-born genetic testing market size, by technology, 2016 – 2020 (USD Million)

TABLE 180.  Japan prenatal and new-born genetic testing market size, by technology, 2021 – 2027 (USD Million)

TABLE 181.  Japan prenatal and new-born genetic testing market size, by screening, 2016 – 2020 (USD Million)

TABLE 182.  Japan prenatal and new-born genetic testing market size, by screening, 2021 – 2027 (USD Million)

TABLE 183.  Japan prenatal and new-born genetic testing market size, by diagnostic, 2016 – 2020 (USD Million)

TABLE 184.  Japan prenatal and new-born genetic testing market size, by diagnostic, 2021 – 2027 (USD Million)

TABLE 185.  Japan prenatal and new-born genetic testing market size, by disease, 2016 – 2020 (USD Million)

TABLE 186.  Japan prenatal and new-born genetic testing market size, by disease, 2021 – 2027 (USD Million)

TABLE 187.  Japan prenatal and new-born genetic testing market size, by end–use, 2016 – 2020 (USD Million)

TABLE 188.  Japan prenatal and new-born genetic testing market size, by end–use, 2021 – 2027 (USD Million)

TABLE 189.  Australia prenatal and new-born genetic testing market size, by technology, 2016 – 2020 (USD Million)

TABLE 190.  Australia prenatal and new-born genetic testing market size, by technology, 2021 – 2027 (USD Million)

TABLE 191.  Australia prenatal and new-born genetic testing market size, by screening, 2016 – 2020 (USD Million)

TABLE 192.  Australia prenatal and new-born genetic testing market size, by screening, 2021 – 2027 (USD Million)

TABLE 193.  Australia prenatal and new-born genetic testing market size, by diagnostic, 2016 – 2020 (USD Million)

TABLE 194.  Australia prenatal and new-born genetic testing market size, by diagnostic, 2021 – 2027 (USD Million)

TABLE 195.  Australia prenatal and new-born genetic testing market size, by disease, 2016 – 2020 (USD Million)

TABLE 196.  Australia prenatal and new-born genetic testing market size, by disease, 2021 – 2027 (USD Million)

TABLE 197.  Australia prenatal and new-born genetic testing market size, by end–use, 2016 – 2020 (USD Million)

TABLE 198.  Australia prenatal and new-born genetic testing market size, by end–use, 2021 – 2027 (USD Million)

TABLE 199.  Latin America prenatal and new-born genetic testing market size, by country, 2016 – 2020 (USD Million)

TABLE 200.  Latin America prenatal and new-born genetic testing market size, by country, 2021 – 2027 (USD Million)

TABLE 201.  Latin America prenatal and new-born genetic testing market size, by technology, 2016 – 2020 (USD Million)

TABLE 202.  Latin America prenatal and new-born genetic testing market size, by technology, 2021 – 2027 (USD Million)

TABLE 203.  Latin America prenatal and new-born genetic testing market size, by screening, 2016 – 2020 (USD Million)

TABLE 204.  Latin America prenatal and new-born genetic testing market size, by screening, 2021 – 2027 (USD Million)

TABLE 205.  Latin America prenatal and new-born genetic testing market size, by diagnostic, 2016 – 2020 (USD Million)

TABLE 206.  Latin America prenatal and new-born genetic testing market size, by diagnostic, 2021 – 2027 (USD Million)

TABLE 207.  Latin America prenatal and new-born genetic testing market size, by disease, 2016 – 2020 (USD Million)

TABLE 208.  Latin America prenatal and new-born genetic testing market size, by disease, 2021 – 2027 (USD Million)

TABLE 209.  Latin America prenatal and new-born genetic testing market size, by end–use, 2016 – 2020 (USD Million)

TABLE 210.  Latin America prenatal and new-born genetic testing market size, by end–use, 2021 – 2027 (USD Million)

TABLE 211.  Brazil prenatal and new-born genetic testing market size, by technology, 2016 – 2020 (USD Million)

TABLE 212.  Brazil prenatal and new-born genetic testing market size, by technology, 2021 – 2027 (USD Million)

TABLE 213.  Brazil prenatal and new-born genetic testing market size, by screening, 2016 – 2020 (USD Million)

TABLE 214.  Brazil prenatal and new-born genetic testing market size, by screening, 2021 – 2027 (USD Million)

TABLE 215.  Brazil prenatal and new-born genetic testing market size, by diagnostic, 2016 – 2020 (USD Million)

TABLE 216.  Brazil prenatal and new-born genetic testing market size, by diagnostic, 2021 – 2027 (USD Million)

TABLE 217.  Brazil prenatal and new-born genetic testing market size, by disease, 2016 – 2020 (USD Million)

TABLE 218.  Brazil prenatal and new-born genetic testing market size, by disease, 2021 – 2027 (USD Million)

TABLE 219.  Brazil prenatal and new-born genetic testing market size, by end–use, 2016 – 2020 (USD Million)

TABLE 220.  Brazil prenatal and new-born genetic testing market size, by end–use, 2021 – 2027 (USD Million)

TABLE 221.  Mexico prenatal and new-born genetic testing market size, by technology, 2016 – 2020 (USD Million)

TABLE 222.  Mexico prenatal and new-born genetic testing market size, by technology, 2021 – 2027 (USD Million)

TABLE 223.  Mexico prenatal and new-born genetic testing market size, by screening, 2016 – 2020 (USD Million)

TABLE 224.  Mexico prenatal and new-born genetic testing market size, by screening, 2021 – 2027 (USD Million)

TABLE 225.  Mexico prenatal and new-born genetic testing market size, by diagnostic, 2016 – 2020 (USD Million)

TABLE 226.  Mexico prenatal and new-born genetic testing market size, by diagnostic, 2021 – 2027 (USD Million)

TABLE 227.  Mexico prenatal and new-born genetic testing market size, by disease, 2016 – 2020 (USD Million)

TABLE 228.  Mexico prenatal and new-born genetic testing market size, by disease, 2021 – 2027 (USD Million)

TABLE 229.  Mexico prenatal and new-born genetic testing market size, by end–use, 2016 – 2020 (USD Million)

TABLE 230.  Mexico prenatal and new-born genetic testing market size, by end–use, 2021 – 2027 (USD Million)

TABLE 231.  Argentina prenatal and new-born genetic testing market size, by technology, 2016 – 2020 (USD Million)

TABLE 232.  Argentina prenatal and new-born genetic testing market size, by technology, 2021 – 2027 (USD Million)

TABLE 233.  Argentina prenatal and new-born genetic testing market size, by screening, 2016 – 2020 (USD Million)

TABLE 234.  Argentina prenatal and new-born genetic testing market size, by screening, 2021 – 2027 (USD Million)

TABLE 235.  Argentina prenatal and new-born genetic testing market size, by diagnostic, 2016 – 2020 (USD Million)

TABLE 236.  Argentina prenatal and new-born genetic testing market size, by diagnostic, 2021 – 2027 (USD Million)

TABLE 237.  Argentina prenatal and new-born genetic testing market size, by disease, 2016 – 2020 (USD Million)

TABLE 238.  Argentina prenatal and new-born genetic testing market size, by disease, 2021 – 2027 (USD Million)

TABLE 239.  Argentina prenatal and new-born genetic testing market size, by end–use, 2016 – 2020 (USD Million)

TABLE 240.  Argentina prenatal and new-born genetic testing market size, by end–use, 2021 – 2027 (USD Million)

TABLE 241.  MEA prenatal and new-born genetic testing market size, by country, 2016 – 2020 (USD Million)

TABLE 242.  MEA prenatal and new-born genetic testing market size, by country, 2021 – 2027 (USD Million)

TABLE 243.  MEA prenatal and new-born genetic testing market size, by technology, 2016 – 2020 (USD Million)

TABLE 244.  MEA prenatal and new-born genetic testing market size, by technology, 2021 – 2027 (USD Million)

TABLE 245.  MEA prenatal and new-born genetic testing market size, by screening, 2016 – 2020 (USD Million)

TABLE 246.  MEA prenatal and new-born genetic testing market size, by screening, 2021 – 2027 (USD Million)

TABLE 247.  MEA prenatal and new-born genetic testing market size, by diagnostic, 2016 – 2020 (USD Million)

TABLE 248.  MEA prenatal and new-born genetic testing market size, by diagnostic, 2021 – 2027 (USD Million)

TABLE 249.  MEA prenatal and new-born genetic testing market size, by disease, 2016 – 2020 (USD Million)

TABLE 250.  MEA prenatal and new-born genetic testing market size, by disease, 2021 – 2027 (USD Million)

TABLE 251.  MEA prenatal and new-born genetic testing market size, by end–use, 2016 – 2020 (USD Million)

TABLE 252.  MEA prenatal and new-born genetic testing market size, by end–use, 2021 – 2027 (USD Million)

TABLE 253.  South Africa prenatal and new-born genetic testing market size, by technology, 2016 – 2020 (USD Million)

TABLE 254.  South Africa prenatal and new-born genetic testing market size, by technology, 2021 – 2027 (USD Million)

TABLE 255.  South Africa prenatal and new-born genetic testing market size, by screening, 2016 – 2020 (USD Million)

TABLE 256.  South Africa prenatal and new-born genetic testing market size, by screening, 2021 – 2027 (USD Million)

TABLE 257.  South Africa prenatal and new-born genetic testing market size, by diagnostic, 2016 – 2020 (USD Million)

TABLE 258.  South Africa prenatal and new-born genetic testing market size, by diagnostic, 2021 – 2027 (USD Million)

TABLE 259.  South Africa prenatal and new-born genetic testing market size, by disease, 2016 – 2020 (USD Million)

TABLE 260.  South Africa prenatal and new-born genetic testing market size, by disease, 2021 – 2027 (USD Million)

TABLE 261.  South Africa prenatal and new-born genetic testing market size, by end–use, 2016 – 2020 (USD Million)

TABLE 262.  South Africa prenatal and new-born genetic testing market size, by end–use, 2021 – 2027 (USD Million)

TABLE 263.  Saudi Arabia prenatal and new-born genetic testing market size, by technology, 2016 – 2020 (USD Million)

TABLE 264.  Saudi Arabia prenatal and new-born genetic testing market size, by technology, 2021 – 2027 (USD Million)

TABLE 265.  Saudi Arabia prenatal and new-born genetic testing market size, by screening, 2016 – 2020 (USD Million)

TABLE 266.  Saudi Arabia prenatal and new-born genetic testing market size, by screening, 2021 – 2027 (USD Million)

TABLE 267.  Saudi Arabia prenatal and new-born genetic testing market size, by diagnostic, 2016 – 2020 (USD Million)

TABLE 268.  Saudi Arabia prenatal and new-born genetic testing market size, by diagnostic, 2021 – 2027 (USD Million)

TABLE 269.  Saudi Arabia prenatal and new-born genetic testing market size, by disease, 2016 – 2020 (USD Million)

TABLE 270.  Saudi Arabia prenatal and new-born genetic testing market size, by disease, 2021 – 2027 (USD Million)

TABLE 271.  Saudi Arabia prenatal and new-born genetic testing market size, by end–use, 2016 – 2020 (USD Million)

TABLE 272.  Saudi Arabia prenatal and new-born genetic testing market size, by end–use, 2021 – 2027 (USD Million)

Charts and Figures

FIG. 1    Market estimation and forecast methodology

FIG. 2    Top-down approach (supply side analysis)

FIG. 3    Bottom-up approach (demand side analysis)

FIG. 4    Industry segmentation

FIG. 5    Global prenatal and new-born genetic testing market size, 2016 – 2027 (USD Million)

FIG. 6    Growth potential analysis, by technology

FIG. 7    Growth potential analysis, by disease

FIG. 8    Growth potential analysis, by end-use

FIG. 9    Porter’s analysis

FIG. 10  Competitive matrix analysis

FIG. 11  PESTEL analysis

FIG. 12  Key segment trends, by technology

FIG. 13  Key segment trends, by disease

FIG. 14  Key segment trends, by end-use

FIG. 15  Key regional trends

Segmentation

Market, Based on Technology  (USD Million)

  • Screening
    • Non-invasive (NIPT)
    • Chorionic Villus Sampling (CVS)
    • Amniocentesis
    • Maternal Sulcer Screening (MSS)
    • Other
  • Diagnostic
    • mmPCR
    • Spectrophotometer
    • FISH
    • ASSAYS
    • Other

Market, by Disease (USD Million)

  • Down’s Syndrome
  • Phenylketonuria
  • Cystic Fibrosis
  • Sickle Cell Anaemia
  • Other

Market, By End-Use  (USD Million)

  • Hospital
  • Specialist and Maternity Clinics
  • Diagnostic Centers

Major Companies

  • Bio-Rad Laboratories Inc.
  • F. Hoffmann La-Roche Ltd.
  • PerkinElmer, Inc.
  • Natera, Inc.
  • Agilent Technologies Inc.
  • Illumina, Inc.
  • Natera Inc.
  • Quest Diagnostics Incorporated
  • Others

Why Choose MWR

Quality Research

Our goal is to provide high-quality data that stimulates growth and creates a win-win situations

Unlimited User Access 

We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions

Free Company Inclusion 

We give you an option to include 3-4 additional company players of your choice in our report without any extra charges

Post Sale Assistance

Unlimited post sales service with an account manager dedicated to making sure that all your needs are met

Covid-19 Impact Analysis

All our research report includes latest Covid-19 Impact and its analysis

Download Free Sample PDF

444 Alaska Avenue

Suite #BAA205 Torrance, CA 90503 USA

+1 424 360 2221

24/7 Customer Support

Download Free Sample PDF